Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Other Working Capital · Q2 FY2026 · quarter ended Jun 2026
Other working capital dips below year-ago levels
Q2 FY2026 other working capital of $646K (cash outflow) fell 84.8% year over year, behind the +72.1% change in trailing-twelve-month other working capital. Sequentially, it fell 84.3% from the prior quarter. Over 3 fiscal years it compounded at -11.3% a year.
Context
- Other working capital amounted to 11.5% of revenue in FY2025, up 0.7 pp from a year earlier.
- Other working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -84.8% toward the trailing-twelve-month pace of +72.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (21.45M) USD
- Year-over-year change
- +23.6%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.45M) | +23.6% |
| FY2024 | 2024-12-31 | (28.07M) | -473.5% |
| FY2023 | 2023-12-31 | 7.52M | +124.5% |
| FY2022 | 2022-12-31 | (30.69M) | +64.0% |
| FY2021 | 2021-12-31 | (85.34M) | — |
Other Working Capital vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 other working capital of $18.28M is the 4th largest of the 9 companies compared; the peer median is $6.57M.
- Its year-over-year change of +72.1% is the 5th highest of 9, against a peer median of +69.6%.
- Other working capital amounts to 8.8% of revenue for MRVI, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $90.39M | +421.0% | +91.1% | 104.8% | |
| LTM Sep 2026 | $60.82M | +258.3% | -4.4% | 5.0% | |
| LTM Jun 2026 | $52.9M | -119.7% | — | 2.0% | |
| LTM Jun 2026 | $18.28M | +72.1% | -11.3% | 8.8% | |
| LTM Mar 2026 | $10.11M | +197.9% | — | 6.3% | |
| LTM Jun 2026 | $9.75M | -58.7% | +159.0% | 1.2% | |
| LTM Aug 2026 | $8.15M | -3805.0% | — | 0.9% | |
| LTM Sep 2026 | $4.99M | -248.5% | -55.6% | 0.8% | |
| LTM Mar 2026 | $2.74M | +627.1% | — | 2.7% | |
| Peer median (excluding MRVI) | $6.57M | +69.6% | +43.4% | 2.4% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 469.25M | 490.66M | (119.03M) | (259.62M) | (130.77M) |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| Deferred Income Tax | 46.9M | 42.32M | 754.94M | 2.32M | (20K) |
| Stock-Based Compensation | 10.46M | 18.67M | 34.59M | 49.42M | 0 |
| Change in Working Capital | (176.63M) | (45.08M) | 97.84M | (12.61M) | (7.98M) |
| Accounts Receivables | (70.39M) | (22.27M) | 84.4M | 14.36M | 12.82M |
| Inventory | (21.57M) | 9.46M | 649K | 377K | 8M |
| Accounts Payables | 676K | (1.58M) | 5.28M | 723K | (7.35M) |
| Other Working Capital | (85.34M) | (30.69M) | 7.52M | (28.07M) | (21.45M) |
| Other Non-Cash Items | (6.16M) | (8.7M) | (690.9M) | 171.1M | 20.73M |
| Operating Cash Flow | 368.57M | 535.98M | 126.22M | 7.47M | (57.57M) |
| Capital Expenditures | (14.85M) | (17.09M) | (65.55M) | (29.66M) | (13.15M) |
| Acquisitions (Net) | 119.96M | (238.35M) | (69.62M) | 0 | (18.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 548K | (12.17M) | 12.87M | 5.34M | 0 |
| Investing Cash Flow | 105.66M | (267.61M) | (122.31M) | (24.32M) | (31.41M) |
| Debt Repayment | (6M) | (5.44M) | (5.77M) | (234.07M) | (5.44M) |
| Common Stock Issued | 1.71M | 2.36M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (20K) | (2.08M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (154.76M) | (184.42M) | (55.3M) | 443K | (11.06M) |
| Financing Cash Flow | (159.05M) | (187.5M) | (61.09M) | (235.71M) | (16.5M) |
| Effect of Forex Changes | (88K) | 0 | 0 | 0 | (32K) |
| Net Change in Cash | 315.09M | 80.87M | (57.18M) | (252.56M) | (105.51M) |
| Free Cash Flow | 353.72M | 518.89M | 60.67M | (22.19M) | (70.72M) |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.